Skip to main
LXRX
LXRX logo

Lexicon Pharmaceuticals (LXRX) Stock Forecast & Price Target

Lexicon Pharmaceuticals (LXRX) Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 20%
Buy 10%
Hold 50%
Sell 20%
Strong Sell 0%

Bulls say

Lexicon Pharmaceuticals Inc. recently achieved favorable topline results from the Phase 2b PROGRESS clinical trial for its drug candidate LX9211, which targets diabetic peripheral neuropathic pain (DPNP), thereby enhancing confidence in its therapeutic potential. The positive clinical outcomes, coupled with robust partnership interest and a significant addressable market of approximately 9 million diagnosed cases of DPNP in the U.S., indicate strong prospects for revenue generation. In addition, the company’s strategy to expand market penetration for existing treatments while introducing earlier-stage assets, such as LX9851 for obesity and cardiometabolic conditions, further supports a positive outlook for its stock performance.

Bears say

Lexicon Pharmaceuticals faces a negative outlook primarily due to disappointing clinical trial results, particularly with its 20 mg dose of RELIEF DPN-1, which failed to achieve statistical significance compared to placebo despite some positive data observed at different dose levels. The potential for future setbacks looms large given the risks associated with inconclusive trial outcomes and the company’s challenges in securing sufficient funding to advance its drug development pipeline. Additionally, concerns regarding tolerability issues and high dropout rates further contribute to skepticism around the company's ability to generate value from its drug candidates.

Lexicon Pharmaceuticals (LXRX) has been analyzed by 10 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 10% recommend Buy, 50% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lexicon Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lexicon Pharmaceuticals (LXRX) Forecast

Analysts have given Lexicon Pharmaceuticals (LXRX) a Hold based on their latest research and market trends.

According to 10 analysts, Lexicon Pharmaceuticals (LXRX) has a Hold consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lexicon Pharmaceuticals (LXRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.